BMY - Bristol-Myers Squibb Company
51.61 0.00 (0.00%)
After hours: 4:18PM EDT
| Previous Close | 52.30 |
| Open | 52.35 |
| Bid | 51.63 x 29700 |
| Ask | 51.66 x 2400 |
| Day's Range | 51.51 - 52.54 |
| 52 Week Range | 51.51 - 70.05 |
| Volume | 16,779,326 |
| Avg. Volume | 8,679,185 |
| Market Cap | 84.383B |
| Beta | 1.04 |
| PE Ratio (TTM) | 84.61 |
| EPS (TTM) | 0.61 |
| Earnings Date | Apr 26, 2018 |
| Forward Dividend & Yield | 1.60 (2.96%) |
| Ex-Dividend Date | 2018-04-05 |
| 1y Target Est | 62.60 |
- Market Realist•9 hours ago
Cabometyx Could Be Exelixis’s Long-Term Growth Driver
In March 2018, the FDA accepted Exelixis’s (EXEL) supplemental New Drug Application (or sNDA) for Cabometyx as a therapy for the treatment of individuals with advanced hepatocellular carcinoma (or HCC) who have previously undergone therapy. Exelixis’s sNDA was based on the results of its Phase 3 CELESTIAL trial. In October 2017, an independent data-monitoring committee recommended that Exelixis stop its CELESTIAL efficacy trial after a review of the second planned interim analysis, wherein Cabometyx demonstrated statistically significant and clinically meaningful progress in overall survival compared to the placebo in individuals who had already been treated for advanced HCC.
Market Realist•23 hours agoHow Exelixis’s Cabomeytx and Cometriq Performed in 4Q17 and 2017
In 4Q17, Exelixis’s (EXEL) Cabometyx reported revenue of $90.4 million compared to $44.7 million in 4Q16, which reflected a ~102% rise on a YoY (year-over-year) basis. The FDA’s approval of the drug’s label expansion also boosted its revenue growth in 4Q17. In 2017, Cabometyx generated revenue of $324 million compared to $93.5 million in 2016.
- Business Wire•yesterday
U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Patients with Small Cell Lung Cancer and Grants Priority Review
Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has accepted for priority review its supplemental Biologics License Application for Opdivo to treat patients with small cell lung cancer whose disease has progressed after two or more prior lines of therapy.
Market Realist•yesterdayAnalysts’ Recommendations for AbbVie in April 2018
In April 2018, the FDA notified AbbVie (ABBV) and Neurocrine Biosciences that it would need more time to review liver function test data provided by AbbVie with its new drug application for Elagolix for the management of endometriosis-associated pain, extending its Prescription Drug User Fee Act goal date by three months to 3Q18. In 4Q17, the FDA granted Elagolix priority review. In clinical trials, Elagolix was evaluated for safety and efficacy in ~1,700 women with moderate-to-severe endometriosis-related pain.
- ACCESSWIRE•yesterday
The Newest, Undiscovered CAR-T Play with a Rock-Star Partner Portfolio & Significant Near-Term Upside Potential
- Cell therapies an emerging treatment modality, expected to blossom into $25 billion-plus industry within a decade. Manufacturing is complex, costing $50K+ per patient, and many companies turn to contract manufacturers for help with development and commercial readiness. NEW YORK, NY / ACCESSWIRE / April 18, 2018 / Cell therapies are lined up to be one of the largest new biomedical breakthroughs in decades.
Market Realist•yesterdayAbbVie’s Duodopa, Creon, Synagis, Synthroid, and Sevoflurane
In 4Q17, AbbVie’s (ABBV) Duodopa generated revenue of $100 million, marking ~28% growth YoY (year-over-year) and 6% growth quarter-over-quarter. In US and international markets, Duodopa saw revenue of $17 million and $77 million, respectively, reflecting ~55.2% and ~23% growth YoY.
- Bloomberg•2 days ago
Coke Versus Pepsi of Drugmakers? Wall Street Doesn't Buy It
Hours after markets closed on Bristol-Myers Squibb Co.’s worst day in more than a year, executives used a sugary analogy to explain to Wall Street why the drugmaker’s new cancer treatment would do just ...
- Benzinga•2 days ago
One Up, One Down: Morgan Stanley Flips Merck, Bristol-Myers Ratings
Merck & Co., Inc. (NYSE: MRK )’s Keytruda returned better-than-expected results in the Keynote-189 lung study — a feat seen to lend a competitive edge over Bristol-Myers Squibb Co (NYSE: BMY ). The Rating ...
- Simply Wall St.•2 days ago
Calculating The Intrinsic Value Of Bristol-Myers Squibb Company (NYSE:BMY)
In this article I am going to calculate the intrinsic value of Bristol-Myers Squibb Company (NYSE:BMY) using the discounted cash flows (DCF) model. Anyone interested in learning a bit moreRead More...
- Zacks•2 days ago
Bristol-Myers (BMY) Down as Merck NSCLC Study Fares Better
Bristol-Myers (BMY) stock declined as the company reported encouraging results from its NSCLC study but competitor Merck scored better in the same regard.
InvestorPlace•2 days agoStocks Push Forward As Fears of War Diminish
U.S. stock futures are up today with the S&P 500 up 0.5%, the Dow Jones Industrial Average up 0.78% and the Nasdaq Composite up 0.54%. This comes as stocks shrugged off the U.S.-led airstrike on Syria over the weekend.
Yahoo Finance Video•6 hours agoEARNINGS: Philip Morris misses on revenue, selling fewer cigarettes in Saudi Arabia
Yahoo Finance's Jared Blikre and Alexis Christoforous break down the latest market action.
- CNBC Videos•yesterday
Trader adding to this beaten pharma stock
Kari Firestone, Aureus Asset Management, discusses why she is adding to her position in Bristol-Myers.
Yahoo Finance Video•2 days agoMARKETS: Wall Street's biggest fear is a trade war and FAANG+BAT is still the most crowded trade
Yahoo Finance's Jared Blikre and Alexis Christoforous break down the latest market action.
